Results 261 to 270 of about 87,373 (338)

Exploring cellular changes in ruptured human quadriceps tendons at single‐cell resolution

The Journal of Physiology, EarlyView.
Abstract figure legend This study explores the cellular landscape of healthy and ruptured quadriceps tendons using single nucleus RNA sequencing. While a range of stromal and immune cell types and subsets were identified, the data indicate that fibroblasts and endothelial cells are the main drivers of the early injury response within ruptured ...
Jolet Y. Mimpen, Mathew J. Baldwin, Claudia Paul, Lorenzo Ramos‐Mucci, Alina Kurjan, Carla J. Cohen, Shreeya Sharma, Marie S. N. Chevalier Florquin, Philippa A. Hulley, John McMaster, Andrew Titchener, Alexander Martin, Matthew L. Costa, Stephen E. Gwilym, Adam P. Cribbs, Sarah J. B. Snelling   +15 more
wiley   +1 more source

An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy. [PDF]

Leukemia
Stewart G, Tazzyman S, Sun Y, Andrews RE, Harrison J, Lath D, Down J, Robinson G, Wang X, Muthana M, Chantry AD, Lawson MA.   +11 more
europepmc   +1 more source

Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract The peripheral T‐cell lymphomas (PTCL) are the only disease for which four histone deacetylase (HDAC) inhibitors have been approved globally as single agents. Although it is not clear why the PTCL exhibit such a vulnerability to these drugs, understanding the biological basis for this activity is essential.
Ariana Sabzevari, Johnson Ung, Jeffrey W. Craig, Kallesh D. Jayappa, Ipsita Pal, David J. Feith, Thomas P. Loughran Jr, Owen A. O’Connor   +7 more
wiley   +1 more source

Hiding in Plain Sight: Cell Biomimicry for Improving Hematological Cancer Outcomes. [PDF]

Nanomaterials (Basel)
Weinstein LA, Wei B.
europepmc   +1 more source

GREM1 deficiency induced bone marrow adipose niche promotes B‐cell acute lymphoblastic leukemia disease progression

International Journal of Cancer, Volume 157, Issue 3, Page 559-572, 1 August 2025.
What's new? Too often, children treated for B‐cell acute lymphocytic leukemia (B‐ALL) experience relapse. Here, the authors investigate the role of dyslipidemia in leukemia progression. Higher adipogenicity in bone marrow mesenchymal stem cells, and increased triglyceride accumulation, are associated with higher risk of death.
Lili Song, Rui Zhang, Liya Pan, Qiang Mi, Yi Yang, Xiang Wang, Yani Ma, Shuhong Shen, Benshang Li, Yanxin Li, Li Hong   +10 more
wiley   +1 more source

Lipid metabolism in multiple myeloma: pathogenesis, therapeutic opportunities, and future directions. [PDF]

Front Oncol
Wang H, Zhang J, Ren H, Chen L, Ren J, Liu C, Wu H, Zhou L.   +7 more
europepmc   +1 more source

Prospective evaluation of 92 protein biomarkers for early detection of endometrial cancer

International Journal of Cancer, Volume 157, Issue 3, Page 480-489, 1 August 2025.
What's new? In this prospective study, the authors evaluated the discrimination capacity of 92 cancer‐related proteins as potential early detection biomarkers for endometrial cancer using blood samples from two large‐scale European population cohorts (EPIC and Janus).
Victoria Cooley, Renée Turzanski Fortner, Trasias Mukama, Sabine Naudin, Valeria Pala, Laure Dossus, Inger T. Gram, Karina Standahl Olsen, Maria‐Jose Sánchez, Pernilla Israelsson, Naomi Allen, Hilde Langseth, Rudolf Kaaks   +12 more
wiley   +1 more source

Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities. [PDF]

Biomolecules
Hu S, Xu J, Cui W, Jin H, Wang X, Maimaitiyiming Y.   +5 more
europepmc   +1 more source

Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis

Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 95-105, July 2025.
After a medicine has been tested in pivotal trials, regulators, health technology assessment (HTA) organizations, and professional societies make decisions about the patients best served by the medicine. This study assesses how the patient populations for oncology medicines (2010–2023) are defined (1) at trial, (2) regulatory submission, (3) upon ...
Milou A. Hogervorst, Rick A. Vreman, Theresa A. Oduol, Aukje K. Mantel‐Teeuwisse, Wim G. Goettsch, Aaron S. Kesselheim   +5 more
wiley   +1 more source